Commodore Capital LP Cuts Stake in Xenon Pharmaceuticals Inc. $XENE

Commodore Capital LP cut its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 54.2% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 825,000 shares of the biopharmaceutical company’s stock after selling 975,000 shares during the quarter. Xenon Pharmaceuticals comprises 2.8% of Commodore Capital LP’s portfolio, making the stock its 15th biggest position. Commodore Capital LP’s holdings in Xenon Pharmaceuticals were worth $47,974,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in XENE. Kestra Advisory Services LLC acquired a new stake in Xenon Pharmaceuticals in the fourth quarter valued at approximately $33,000. Blue Trust Inc. grew its position in shares of Xenon Pharmaceuticals by 2,560.7% in the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 717 shares in the last quarter. Danske Bank A S acquired a new position in Xenon Pharmaceuticals in the third quarter valued at approximately $32,000. Caitong International Asset Management Co. Ltd bought a new stake in Xenon Pharmaceuticals in the 4th quarter valued at about $43,000. Finally, Rockefeller Capital Management L.P. grew its holdings in Xenon Pharmaceuticals by 450.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,100 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 900 shares in the last quarter. 95.45% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

XENE has been the topic of several research analyst reports. Needham & Company LLC lowered their price target on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Monday, July 6th. JPMorgan Chase & Co. upped their price objective on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “overweight” rating in a research note on Wednesday, May 27th. Royal Bank Of Canada raised their price target on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “outperform” rating in a research note on Friday, May 8th. Finally, Wells Fargo & Company reaffirmed an “overweight” rating and issued a $69.00 price objective on shares of Xenon Pharmaceuticals in a research note on Sunday, May 10th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $77.20.

Insider Transactions at Xenon Pharmaceuticals

In other news, Director Gillian Cannon sold 1,190 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $63,236.60. Following the sale, the director directly owned 1,455 shares in the company, valued at $77,318.70. This trade represents a 44.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gary Patou sold 1,322 shares of the stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $70,251.08. Following the completion of the sale, the director owned 24,896 shares of the company’s stock, valued at approximately $1,322,973.44. This represents a 5.04% decrease in their position. The SEC filing for this sale provides additional information. 2.91% of the stock is currently owned by company insiders.

Xenon Pharmaceuticals Price Performance

Xenon Pharmaceuticals stock opened at $65.42 on Monday. The company has a market capitalization of $6.32 billion, a PE ratio of -13.92 and a beta of 0.61. Xenon Pharmaceuticals Inc. has a one year low of $30.00 and a one year high of $72.66. The business has a 50 day simple moving average of $58.30 and a 200 day simple moving average of $52.69.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) EPS for the quarter, hitting analysts’ consensus estimates of ($1.17). During the same period last year, the business posted ($0.83) earnings per share. Equities analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.92 earnings per share for the current fiscal year.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.